N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺
N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺
![N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺 结构式](https://img.chemicalbook.com/CAS/GIF/420831-40-9.gif)
N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺 性质
| 密度 | 1.469±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Sealed in dry,2-8°C |
| 溶解度 | 在DMSO中的溶解度≥15mg/mL |
| 形态 | 粉末 |
| 酸度系数(pKa) | 12.28±0.70(Predicted) |
| 颜色 | 白色至棕褐色 |
| 稳定性 | 从购买之日起 2 年内保持稳定。 DMSO 或乙醇溶液可在 -20℃ 下保存长达 3 个月。 |
N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺 用途与合成方法
|
SIRT2 15.5 μM (IC 50 ) |
AK-7 (10 μM) reduces cholesterol levels in naive N2a neuroblastoma cells and hippocampal slice cultures from wild-type mice. AK-7 (1 μM) shows neuroprotective effect of AK-7 in striatal Huntington’s disease (HD) neurons. AK-7 (12.5 μM) decreases ratio of DA neurons in primary midbrain cultures.
AK-7 (15 mg/kg/dose, i.p.) is brain-permeable in wild-type and HD mice. AK-7 (10, 20 mg/kg, i.p.) improves the behavior and neuropathological phenotype and extends survival of R6/2 HD mice. AK-7 (20 mg/kg) ameliorates HD neuropathology in R6/2 mice. AK-7 also reduces the polyglutamine aggregation in R6/2 brain. In addition, AK-7 treated 140CAG mice show motor performance changes that parallel untreated wild-type mice, with the 20 mg/kg dose being most effective and significantly different from untreated 140CAG mice.
N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-25 | HY-16691 | 5 mg | 687 | ||
| 2024-01-25 | HY-16691 | N-(3-溴苯基)-3-[(六氢-1H-氮杂卓-1-基)磺酰基]-苯甲酰胺 | 420831-40-9 | 10mg | 1100 |
